Gabapentin reduces alcohol consumption and craving: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 68, Issue 11, 2007, Pages 1691-1700

  Furieri, Fernando A ^a   Nakamura Palacios, Ester M ^b  

^a Vitória Municipal Addiction Treatment Center   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; GABAPENTIN; PLACEBO; VITAMIN;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; WITHDRAWAL SYNDROME;

EID: 37049018194     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1108     Document Type: Article

References (37)

1. Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 2003;27:232-243
2. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA 1997;278:144-151
3. Prater CD, Miller KE, Zylstra RG. Outpatient detoxification of the addicted or alcoholic patient. Am Fam Physician 1999;60:1175-1183
4. Ait-Daoud N, Malcolm PJ Jr, Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav 2006;31:1628-1649
5. Mariani JJ, Rosenthal RN, Tross S, et al. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict 2006;15:76-84
6. Myrick H, Brady KT, Macolm R. New developments in the pharmacotherapy of alcohol dependence. Am J Addict 2001;10(suppl):3-15
7. Malcolm R, Myrick H, Roberts J, et al. The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict 2002;11:141-150
8. Sutton KG, Martin DJ, Pinnock RD, et al. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 2002;135:257-265
9. 2δ subunits: structure and gabapentin binding. Mol Pharmacol 2001;59:1243-1248
10. Maneuf YP, Gonzales MI, Sutton KS, et al. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 2003;60:742-750
11. LaRoche SM, Helmers SL. The new antiepileptic drugs. JAMA 2004;291:605-614
12. Bailey CP, Molleman A, Little HJ. Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption. Br J Pharmacol 1998;123:215-222
13. Watson WP, Robinson E, Little HJ. The novel anticonvulsivant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology 1997;36:1369-1375
14. Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insonmnia in alcoholic outpatients. Psychiatry Clin Neurosci 2003;57:542-544
15. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal [letter]. Am J Psychiatry 1998;155:1632
16. Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence [letter]. Am J Psychiatry 2000;157:151
17. Emilien G, Maloteaux JM. Pharmacological management of epilepsy: mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities. Int J Clin Pharmacol Ther 1998;36:181-194
18. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
19. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict 1989;84:1353-1357
20. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press; 1992:41-72
21. Bohn MJ, Barton BA, Barron KE. Psychometric and validity of the Obsessive-Compulsive Drinking Scale. Alcohol Clin Exp Res 1996;20:817-823
22. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100
23. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003;361:1677-1685
24. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995;19:92-99
25. de Wildt WAJM, Lehert P, Schippers GM, et al. Investigating the structure of craving using structural equation modeling in analysis of the obsessive-compulsive drinking scale: a multinational study. Alcohol Clin Exp Res 2005;29:509-516
26. Zar JH. Biostatistical Analysis. Upper Saddle River, NJ: Prentice-Hall, Inc; 1999
27. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-249
28. Koob GF. The role of the striatopallidal and extended amygdala systems in drug addiction. Ann N Y Acad Sci 1999;877:445-460
29. Tzchentke TM. The medial prefrontal cortex as a part of the brain reward system. Amino Acids 2000;19:211-219
30. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron 2002;36:229-240
31. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642-1652
32. Lingford-Hughes A, Nutt D. Neurobiology of addiction and implications for treatment. Br J Psychiatry 2003;182:97-100
33. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JF, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York, NY: McGraw-Hill; 2001:521-547
34. Ait-Daoud N, Johnson BA, Prihoda TJ, et al. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 2001;154:23-27
35. Johnson BA, Swift RM, Addolorato G, et al. Safety and efficacy of GABAergic medications for treating alcoholism. Alcohol Clin Exp Res 2005;29:248-254
36. Voris J, Smith NL, Rao SM, et al. Gabapentin for the treatment of ethanol withdrawal. Subst Abus 2003;24:129-132
37. Bonnet U, Banger M, Leweke FM, et al. Treatment of acute alcohol withdrawal with gabapentin: results from a controlled 2-center trial. J Clin Psychopharmacol 2003;23:514-519